[Topical atropine for myopia prevention : Current study situation].

BACKGROUND

Low-dose atropine has emerged as an effective intervention for myopia control in children; however, for a long time the evidence predominantly originated from East Asia.

OBJECTIVE

This article reviews the efficacy, safety, dose-finding and regulatory approval status of topical atropine for myopia control, with particular focus on European populations.

MATERIAL AND

METHODS

Narrative review of selected RCT (randomized controlled trials), meta-analyses, long-term data and regulatory approval information.

RESULTS

Atropine 0.01-0.05% dose-dependently reduces myopia progression. The effects of a 0.01% monotherapy are small to moderate. With Ryjunea® (Santen Pharmaceutical Co., Ltd., Osaka, Japan), a preparation was approved in Europe for the first time in 2025.

CONCLUSION

Topical atropine is effective and well tolerated. Unresolved questions regarding dosing in non-Asian populations, treatment duration and long-term effects on complications should be addressed by further studies.